| Jessica Bennett, APRN | |
|
96 Future Dr, Corbin, KY 40701-8988 | |
| (606) 528-0305 | |
| Not Available |
| Full Name | Jessica Bennett |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 5 Years |
| Location | 96 Future Dr, Corbin, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346870458 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 3014216 (Kentucky) | Secondary |
| 363L00000X | Nurse Practitioner | 3014216 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Corbin | Corbin, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health Medical Group Inc | 5597867184 | 1912 |
News Archive
Five Prime Therapeutics, Inc., a leader in biologics, has relocated into its state-of-the-art drug discovery facility in South San Francisco. The new facility provides FivePrime with a two fold increase in square footage without significant incremental rental cost. The relocation includes an expanded laboratory facility for the Company to accelerate its innovative and proprietary protein therapeutic and antibody drug discovery platform.
Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.
The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not "mild". Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don't.
Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.
› Verified 8 days ago
| Entity Name | Ho Medical & Chiropractic Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487667770 PECOS PAC ID: 8426949959 Enrollment ID: O20040505001764 |
News Archive
Five Prime Therapeutics, Inc., a leader in biologics, has relocated into its state-of-the-art drug discovery facility in South San Francisco. The new facility provides FivePrime with a two fold increase in square footage without significant incremental rental cost. The relocation includes an expanded laboratory facility for the Company to accelerate its innovative and proprietary protein therapeutic and antibody drug discovery platform.
Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.
The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not "mild". Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don't.
Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.
› Verified 8 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740586213 PECOS PAC ID: 5597867184 Enrollment ID: O20070228000503 |
News Archive
Five Prime Therapeutics, Inc., a leader in biologics, has relocated into its state-of-the-art drug discovery facility in South San Francisco. The new facility provides FivePrime with a two fold increase in square footage without significant incremental rental cost. The relocation includes an expanded laboratory facility for the Company to accelerate its innovative and proprietary protein therapeutic and antibody drug discovery platform.
Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.
The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not "mild". Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don't.
Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.
› Verified 8 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518360296 PECOS PAC ID: 5597867184 Enrollment ID: O20150206000249 |
News Archive
Five Prime Therapeutics, Inc., a leader in biologics, has relocated into its state-of-the-art drug discovery facility in South San Francisco. The new facility provides FivePrime with a two fold increase in square footage without significant incremental rental cost. The relocation includes an expanded laboratory facility for the Company to accelerate its innovative and proprietary protein therapeutic and antibody drug discovery platform.
Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.
The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not "mild". Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don't.
Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.
› Verified 8 days ago
| Entity Name | Trinity Family Health Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942708706 PECOS PAC ID: 2567726748 Enrollment ID: O20180516002026 |
News Archive
Five Prime Therapeutics, Inc., a leader in biologics, has relocated into its state-of-the-art drug discovery facility in South San Francisco. The new facility provides FivePrime with a two fold increase in square footage without significant incremental rental cost. The relocation includes an expanded laboratory facility for the Company to accelerate its innovative and proprietary protein therapeutic and antibody drug discovery platform.
Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.
The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not "mild". Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don't.
Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jessica Bennett, APRN 96 Future Dr, Corbin, KY 40701-8988 Ph: (606) 528-0305 | Jessica Bennett, APRN 96 Future Dr, Corbin, KY 40701-8988 Ph: (606) 528-0305 |
News Archive
Five Prime Therapeutics, Inc., a leader in biologics, has relocated into its state-of-the-art drug discovery facility in South San Francisco. The new facility provides FivePrime with a two fold increase in square footage without significant incremental rental cost. The relocation includes an expanded laboratory facility for the Company to accelerate its innovative and proprietary protein therapeutic and antibody drug discovery platform.
Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.
The severity of traumatic brain injury is currently crudely classified as mild, moderate or severe. However, often patients referred to as mild have debilitating symptoms that are not "mild". Additionally, there are patients currently classified as moderate or severe who regain their pre-injury functional status whereas others don't.
Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.
› Verified 8 days ago